Bristol-Myers' hep C combo wins Japanese OK, leading the pack

July 7, 2014 4:06 PM

9 0

Bristol-Myers Squibb ($BMY) has become the first drugmaker to win regulatory approval for a combination hepatitis C treatment that doesn't require painful injections, picking up a Japanese nod for its all-oral cocktail.

The country's Ministry of Health, Labor and Welfare has OK'd a combination of the NS5A inhibitor daclatasvir (Daklinza) and the NS3/4A protease inhibitor asunaprevir (Sunvepra), making the combo the world's first interferon- and ribavirin-free treatment regimen to be approved. The drug is indicated ...

Also read: Texas IT company building global headquarters in S. Carolina

Read more

To category page

Loading...